Advertisement

Topics

Catalyst Biosciences, Inc. Company Profile

07:13 EDT 20th September 2017 | BioPortfolio

Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of engineered proteases that target proteins underlying diseases. Catalyst's discovery platform rapidly creates and optimizes tailor-made protease drug candidates that cleave a wide variety of disease targets, either by improving existing protease drugs or by creating new protease drugs, known as Alterase(TM) therapeutics. Catalyst is focusing its product development efforts on drug candidates for hemophilia, non-hemophilic bleeding, and complement-driven diseases, including the prevention of delayed graft function and inflammation. Catalyst has ongoing research, development, and license agreements with Wyeth Pharmaceuticals, a wholly-owned subsidiary of Pfizer Inc. and MedImmune, LLC, the global biologics unit of AstraZeneca plc. Together, these two partnering agreements total up to nearly $700 million in upfront payments, R&D support, and milestone payments, plus royalties on potential future sales. Catalyst is privately held with backing by leading venture firms, including Burrill & Company, Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures, and Sofinnova Ventures. For more information, please visit www.catbio.com.


News Articles [887 Associated News Articles listed on BioPortfolio]

Reviewing Catalyst Biosciences

Catalyst Biosciences and Fortress Biotech are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valu...

Catalyst Bio's hemophilia B candidate gains EU support for orphan designation

Catalyst Biosciences' coagulation Factor IX variant CB 2679d/ISU304, developed to treat hemophilia B, received a positive opi -More- 

Catalyst Biosciences Announces Positive Factor IX Clinical Data

-- CB 2679d/ISU304 is approximately 22 times more potent than current hemophilia B therapy -- SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:...

Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe

SOUTH SAN FRANCISCO, Calif., May 31, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...

Catalyst Biosciences Reports First Quarter 2017 Financial Results and Provides Corporate Update

-- Raised ~$20 million through an underwritten equity offering -- -- Factor IX Hemophilia B program milestone payment received after completion of IND-enabling toxicology studies -- -- Initiati...

Catalyst Biosciences Announces Issuance of Asia Patents Covering Factor IX Hemophilia Program

-- CB 2679d/ISU304 has patent coverage in all key commercial territories -- SOUTH SAN FRANCISCO, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), today anno...

Financial Milestone Achieved In Catalyst Biosciences' Subcutaneous Factor IX Program

  Life Sciences Jobs   ...

Catalyst Biosciences??? Factor IX Recommended For Orphan Drug Designation In Europe

  Life Sciences Jobs   ...

Drugs and Medications [13 Associated Drugs and Medications listed on BioPortfolio]

Naturally nova scotia hand sanitizer [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Natelle one [Azur Pharma, Inc.]

Natelle OneRx Prenatal Vitamin & Plant-Based DHA Now with 28 mg Iron

Natelle one [Azur Pharma, Inc.]

Natelle®OneRx Prenatal Vitamin & Plant-Based DHA

PubMed Articles [656 Associated PubMed Articles listed on BioPortfolio]

Switch in Catalyst State: Single Bifunctional Bi-State Catalyst for Two Different Reactions.

Disclosed here is a molecular switch which responds to acid-base stimuli and serves as a bi-state catalyst for two different reactions. The two states of the switch serve as a highly active and poorly...

Overcoming the instability of nanoparticle based catalyst films in alkaline electrolysers by self-assembling and self-healing films.

Engineering stable electrodes using highly active catalyst nanopowders for electrochemical water splitting remains a notorious challenge. We report an innovative and general approach for attaining hig...

Isotopic studies of the ammonia decomposition reaction using lithium imide catalyst.

Ammonia decomposition using (15)N labelled ammonia was performed over a lithium imide catalyst with mass spectrometry. The results show that all the nitrogen is released from the bulk of the lithium i...

Microstructural observation of fuel cell catalyst inks by Cryo-SEM and Cryo-TEM.

In order to improve the electricity generation performance of fuel cell electric vehicles, it is necessary to optimize the microstructure of the catalyst layer of a polymer electrolyte fuel cell. The ...

Deactivation of a Cobalt Catalyst for Water Reduction via Valence Tautomerism.

The activity of the water reduction catalyst [CoIII(L1)(pyr)2]PF6 (1), where (L1)-2 is a bis-amido pyridine ligand and pyr is pyrrolidine, is investigated. Catalyst 1 has an overpotential of 0.54 V an...

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

The purpose of this research is to determine if a subject's own bone marrow tissue can help regenerate bone in the area of his/her jaw where a tooth has been removed using Tissue Repair Ce...

Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data

We seek to improve the predictive accuracy of the nomogram to predict survival for patients with castrate mets disease through the addition of pathological data, the results of automated m...

Validation of Decipher Test in African American Men With Prostate Cancer - VANDAAM

The primary purpose of this study is to determine whether a tumor test recently developed by GenomeDx Biosciences known as Decipher® can predict aggressive prostate cancer with the same a...

Validation of Lophius Kits T-Track® CMV and T-Track® EBV in Hemodialysis Patients

Cell-mediated immunity (CMI) and in particular T cells play a critical role in the rejection of transplanted organs. Thus, in transplant recipients a life-long and individualized immunosup...

Basic Knowledge of CPR Among Close Relatives of Heart Patients-check Status Quo and Attemp to Establish a Potential Plan to Implement This Knowledge

Cardiac arrest is a public health problem and is the leading cause of death in many parts of the world. Cardiac arrest can occur inside the hospital and outside it. In the United States a...

Companies [435 Associated Companies listed on BioPortfolio]

Targacept, Inc. and Catalyst Biosciences, Inc.

Catalyst Biosciences, Inc.

Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of engineered proteases that target proteins underlying diseases. Catalyst's discovery p...

Catalyst Health and Technology Partners

Catalyst Health and Technology Partners (“Catalyst”), is a venture capital firm dedicated to helping promising early-stage health care, life science, and technology ventures grow.Catalyst is focus...

General Catalyst Partners

General Catalyst Partners is a growth equity and venture capital firm that invests in exceptional entrepreneurs who are building the technology-based companies that will lead inno...

Catalyst Advisors

Catalyst Advisors is a premier executive search firm devoted to finding exceptional boardroom and executive leaders for innovative healthcare and bioscience companies, including t...

More Information about "Catalyst Biosciences, Inc." on BioPortfolio

We have published hundreds of Catalyst Biosciences, Inc. news stories on BioPortfolio along with dozens of Catalyst Biosciences, Inc. Clinical Trials and PubMed Articles about Catalyst Biosciences, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Catalyst Biosciences, Inc. Companies in our database. You can also find out about relevant Catalyst Biosciences, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


Corporate Database Quicklinks



Searches Linking to this Company Record